Prelude Capital Management, LLC Pulmonx Corp Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.77 - $9.82 $23,080 - $39,280	4,000 Added 32.79%	16,200 $102,000
Q1 2024 May 15, 2024	SELL	$8.71 - $14.65 $6,201 - $10,430	-712 Reduced 5.51%	12,200 $113,000
Q4 2023 Feb 14, 2024	BUY	$7.89 - $13.14 $101,875 - $169,663	12,912 New	12,912 $164,000
Q3 2022 Nov 14, 2022	BUY	$15.35 - $23.99 $333,156 - $520,678	21,704 New	21,704 $362,000
Q1 2022 May 16, 2022	SELL	$21.13 - $35.65 $238,769 - $402,845	-11,300 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$29.72 - $45.1 $95,252 - $144,545	3,205 Added 39.59%	11,300 $362,000
Q3 2021 Nov 15, 2021	BUY	$35.98 - $44.48 $3,741 - $4,625	104 Added 1.3%	8,095 $291,000
Q2 2021 Aug 16, 2021	BUY	$37.61 - $48.0 $300,541 - $383,568	7,991 New	7,991 $353,000

123

31M

300

204K

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $236M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.